X
[{"orgOrder":0,"company":"Ducentis BioTherapeutics","sponsor":"Arcutis Biotherapeutics","pharmaFlowCategory":"D","amount":"$30.0 million","upfrontCash":"$16.0 million","newsHeadline":"Arcutis Announces Acquisition of Ducentis BioTherapeutics Ltd.","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"},{"orgOrder":0,"company":"Ducentis BioTherapeutics","sponsor":"Arcutis Biotherapeutics","pharmaFlowCategory":"D","amount":"$400.0 million","upfrontCash":"$16.0 million","newsHeadline":"LifeArc Portfolio Company Ducentis Bio Therapeutics Acquired by Arcutis Biotherapeutics for Up to $400 Million","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Preclinical"}]
Find Clinical Drug Pipeline Developments & Deals by Ducentis BioTherapeutics
Filters
Companies By Therapeutic Area
Details:
DS-234 is a fusion protein that is a highly selective and potent agonist of CD200R, an immune-regulatory receptor thought to be an important immunological checkpoint, with a pivotal role in maintenance of immune tolerance.
Lead Product(s):
DS-234
Therapeutic Area: Dermatology
Product Name: DS-234
Highest Development Status: Preclinical
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Arcutis Biotherapeutics
Deal Size: $400.0 million
Upfront Cash: $16.0 million
Deal Type: Acquisition
September 08, 2022
Details:
DS-234 offers a potential best-in-class profile, as well as a highly complementary treatment option to roflumilast cream which is in late-stage development for atopic dermatitis.
Lead Product(s):
DS-234
Therapeutic Area: Dermatology
Product Name: DS-234
Highest Development Status: Preclinical
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Arcutis Biotherapeutics
Deal Size: $30.0 million
Upfront Cash: $16.0 million
Deal Type: Acquisition
September 07, 2022